Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016164 | 1.00 | KDM1A (0.44) | KDM1AKDM1BNTRK1NTRK3RIPK1 | |
| SCHEMBL21400027 | 0.90 | CHRNB2 (0.46) | NTRK1NTRK3JAK2 | |
| SCHEMBL4291250 | 0.90 | CHRNB2 (0.46) | NTRK1NTRK3JAK2 | |
| SCHEMBL21400030 | 0.90 | CHRNB2 (0.46) | NTRK1NTRK3JAK2 | |
| SCHEMBL18324642 | 0.83 | EPAS1 (0.35) | — | |
| SCHEMBL25052839 | 0.80 | HTR2C (0.49) | KDM1AKDM1BNTRK1JAK2 | |
| SCHEMBL4306200 | 0.80 | HTR2C (0.49) | KDM1AKDM1BNTRK1JAK2 | |
| SCHEMBL17772161 | 0.79 | KDM1A (0.42) | KDM1AKDM1BNTRK1RIPK1JAK2 | |
| SCHEMBL4301534 | 0.79 | PIK3C3 (0.45) | KDM1AKDM1BNTRK1JAK2 | |
| SCHEMBL18790928 | 0.79 | KDM1A (0.49) | KDM1AKDM1BNTRK1NTRK3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9796723-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795611-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9676783-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114068-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8865698-B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130217662-A1 | METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2013-08-22 | — | — | US | disclosed |
| US-8513263-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8450322-B2 | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | KDM1A 1492/4885KDM1B 1859/4885NTRK1 27/4885 |
| US-20170114068-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | KDM1A 967/4885KDM1B 1237/4885NTRK1 466/4885 |
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | KDM1A 967/4885KDM1B 1237/4885NTRK1 466/4885 |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | KDM1A 2479/4885KDM1B 3219/4885NTRK1 7/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | KDM1A 2325/4885KDM1B 3075/4885NTRK1 8/4885 |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | P2RX7, P2RX1, P2RX3 | KDM1A 1481/4885KDM1B 3042/4885NTRK1 2490/4885 |
| US-20130217662-A1 | METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS | COL2A1, COL1A1, IFNAR1 | KDM1A 967/4885KDM1B 1237/4885NTRK1 466/4885 |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | KDM1A 2303/4885KDM1B 3827/4885NTRK1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.